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Sumlnary 
This report outlines the B cell phenotype of transgenic mice that overexpresses  the mouse CTLA- 
4-humanyl  (mCTLA4-H'y1)  protein.  Despite the fact that  these mice prime  CD4 + T  cells 
(Ronchese, F.,  B. Housemann,  S. Hubele, and P. Lane.  1994. J. Exp. Med.  179:809),  antibody 
responses to T-dependent antigens are severely impaired.  In contrast,  T-independent  responses 
are normal which suggests mCTLA4-H'y1 does not act directly on B cells, but acts indirectly 
by impairing T cell help. The impaired antibody defect is associated with impaired class switching, 
with low total immunoglobulin  (Ig)G and antigen-specific IgG responses,  and an  absence of 
germinal center formation in spleen and lymph nodes but not gut-associated tissues. The defective 
germinal center formation is associated with a reduction in the degree of somatic mutation in 
hybridomas made from transgenic mice in comparison with those made from normal mice. It 
seems likely that mCTLA4-H'y1 exerts its effect by blocking an interaction between T  and B 
cells  that  induce T  cell help for B  cells. 
C 
ostimulation through accessory molecules is thought to 
play a crucial role in lymphocyte activation  (1).  One 
critical receptor/ligand interaction is between CD28/CTLA4 
(2,  3) on T  cells and B7 and related molecules on profes- 
sional APCs such as dendritic cells and activated B ceils (4-7). 
Soluble forms of CTLA4 inhibit the induction of prolifera- 
tion in vitro of most CD4 + clones (8) and block MLR reac- 
tions (9). Furthermore, injection of mouse CTLA4-humanyl 
(mCTLA4-H'y1) 1 has  been shown to inhibit  T-dependent 
antibody production in vivo (10),  and rejection of nonvas- 
cularized xenografts in mice (11), although prolongation of 
allograft  survival has  been more modest (12). 
To enable long-term studies of the potential of mCTLA4- 
H'y1 to modulate immune function, we generated transgenic 
mice that expressed mCTLA4-H3,1 in their serum, at levels 
similar  to or greater  than  those achieved in earlier  studies 
(5,  7). Whereas T-dependent antibody responses were pro- 
foundly inhibited in these animals, we found to our surprise 
that priming of CD4 + cells was not impaired.  In fact, para- 
doxically, hyperimmunized transgenic animals had increased 
1 Abbreviations used in this  paper: CD40L, CD40 ligand; f, primary follicle; 
FDC, follicular dendritic cells; gc, germinal center; mCD40-H'y1,  mouse 
CD40-humanyl; mCD40L-mCD8a, soluble CD40 ligand; mCTLA4- 
H3'1, mouse CTLA4-human3~l; NP, nitrophenol; NP-C'yG, (4-hydroxy- 
3-nitrophenyl)-acetyl chicken gamma globulin. 
numbers of antigen-specific CD4 + cells,  shown to be func- 
tional by their capacity to mediate the adoptive transfer of 
an antibody response (13). 
To understand the mechanism of antibody suppression we 
have investigated the transgenic mice more fully. Total Ig and 
IgG isotype levels, together with T-dependent IgG antihapten 
responses, are grossly reduced. This is not attributable to a 
nonspecific effect of the transgene as control transgenic mice 
make normal  antibody responses. T-independent  responses 
are normal, which implies that mCTLA4-H3,1 exerts its effect 
by blocking T  cell help to B cells,  not by affecting B cells 
directly through  B7 and other  CTLA4 ligands.  Germinal 
center formation is absent,  and is correlated with impaired 
switch to IgG isotypes, reduced somatic mutation and selec- 
tion,  and reduced antibody production. 
Materials  and Methods 
Construction of Chimeric Human IgG1 Molecules.  Chimeric im- 
munoglobulin  molecules expressing the extracellular portions  of 
the mouse CTLA4 gene (14) or mouse CD40 gene (15) and the 
human IgG1 constant domains were created as described previously 
(8,  16). 
Production  of  Transgenic Mice.  Transgenic mice  expressing 
mCTLA4-H'y1 and mouse CD40-human',/1  (mCD40-H3'I) were 
produced as described (17) by microinjecting  XbaI-EcoRV frag- 
ments from plasmids expressing the above fusion proteins (16) into 
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mice. Transgenic mice were identified by screening for the expres- 
sion of human IgG1 in the serum. This was achieved using hemag- 
glutination of SRBC coated (using the chromic chloride method) 
with a mouse mAb to human IgG1 (R.10Z) (Recognition Sciences, 
Birmingham, UK). Transgenic  mice were then backcrossed  with 
homozygous C57BL/6 mice that carry the immunoglobulin b al- 
lotype. 
Antigens.  TNP-Ficoll was  prepared by making  the  AECM 
derivative of Ficol1400 (Pharmacia,  Uppsala, Sweden) as described 
by Inman (18). TNP was then conjugated to Ficoll by dissolving 
AECM-Ficoll  in  0.1  M  borate buffer (pH  8.4),  adding  TNP- 
sulphonic acid, and stirring the mixture for 4 h. The mixture was 
then extensively dialyzed against PBS. The immunogenicity of this 
preparation was confirmed by immunizing athymic nude mice (P. 
Lane, unpublished observations). 
2,4-Dinitro-fluorobenzene was  conjugated to KLH and BSA 
(both from Sigma Chemical Co., St. Louis,  MO) using standard 
methods, and the degree of haptenation calculated  as described in 
(19). The succinimide ester of nitrophenol (NP) (ICI, Northwich, 
UK) was conjugated to BSA in 0.1 M borate buffer, pH 8.4, for 
various times at room temperature. Aliquots of the mixture were 
taken at various times and free NP was separated  from that con- 
jugated to protein by Sephadex 25 columns preequilibrated with 
PBS. The succinimide esters of NP and biotin (Sigma  Chemical 
Co.) were also conjugated to human gamma globulin (Sigma Chem- 
ical Co.) under alkaline conditions, and then extensively dialyzed 
against  PBS.  (4-hydroxy-3-nitrophenyl)-acetyl chicken  gamma 
globulin (NP-CyG) was a kind gift from Professor K. Rajewsky 
(Institute for Genetics,  Cologne, Germany). 
Measurement of Antibody Titer and A~nity by ELISA.  Specific 
anti-DNP and anti-NP antibody titers were determined by ELISA. 
Antibody affinities for the haptens NP and DNP were measured 
according to  the method described by Herzenberg et al.  (20). 
DNP10BSA,  DNP3sBSA,  NP11BSA, and  NP3sBSA were coated 
onto 96owell plastic plates (Dynatech Laboratories,  Inc., Chantilly, 
VA) at 50 ~g/ml hapten-carrier conjugate in 0.1 M borate buffer 
(pH 8.4) overnight at 4~  Plates were washed in PBS (pH 7.4) 
with 0.2% Tween 20 (Sigma Chemical Co.), and then blocked with 
PBS containing 1% FCS for i  h at room temperature. Serial dilu- 
tions of serum in PBS containing 1% FCS were then applied, and 
incubated for 4 h at room temperature. After washing, peroxidase- 
labeled specific goat antisera directed against individual mouse iso- 
types  (Southern  Biotechnology Associates,  Birmingham,  AL) 
were added at the dilutions recommended, and binding of specific 
antibodies  was  revealed  with  the peroxidase  substrate,  ABTS  | 
(Boehringer, Mannheim, Mannheim, Germany), diluted in citrate 
buffer (pH 4.6) as recommended. Plates  were read on an ELISA 
reader at 405 nm. 
Measurement of Mouse Immunoglobulin Subclasses and Human 
IgGl.  The concentrations of mouse immunoglobulin isotypes and 
subclasses in the sera of transgenic and control mice were mea- 
sured using radial immunodiffusion plates (RID; Serotec Ltd., Ox- 
ford, UK). Levels of human IgG1 were estimated with RID plates 
provided by the same manufacturer. 
lmmunohistology.  Sections  of spleen,  lymph node, and Peyer's 
patch were taken from control and immunized mice and mounted 
in  Tissue-tek  embedding compound (Miles  Scientific  Division, 
Naperville, IL). 5-/zm frozen serial sections were cut and air dried, 
fixed in acetone at room temperature for 15 min,  and stored in 
air tight containers at  -20~  until use. 
The expression of the transgene was detected using a biotinylated 
anti-human IgG antibody (Jackson Immunoresearch Laboratories, 
Inc., West Grove, PA). Geminal center B cells were identified  by 
staining with biotinylated peanut (Arachis hypogaea) hemagglutinin 
(PNA) (Sigma Chemical Co.). Follicular dendritic cells (FDC) were 
identified in the sections using the rat anti-mouse FDC mAb, FDC- 
M1, generated in our laboratory. This was visualized using a mouse 
F(ab')~ anti-rat IgG (H and L chain-specific)  conjugated to per- 
oxidase (Jackson Immunoresearch Laboratories,  Inc.). For labeling 
of NP-specific plasma cells, and to detect complexes of NP protein 
and antibody trapped on FDC's in follicles, sections were incubated 
with 1 #g/ml of NP-biotin-human-y-globulin (NP-bH3,G) in PBS 
containing  10  mg/ml  of normal  human-y-globulin  to  block 
nonspecific binding. After a 1 h incubation, the sections were washed 
three times in PBS, and endogenous peroxidase was blocked with 
PBS containing 0.3%  H202 and 0.1%  sodium azide.  After fur- 
ther washing to remove traces  of azide,  the cells were incubated 
for 45 rain with streptavidin peroxidase complexes (Vectastain Elite 
ABC; Vector Laboratories,  Inc., Burlingame, CA). All peroxidase 
reactions were developed using di-amino benzidine (1 mg/ml) (Sigma 
Chemical Co.) containing 0.1% H202 in PBS (pH 7.6). Specificity 
was checked on sections from nonimmunized controls, which did 
not bind NP-bH3,G. Immune complex trapping was assessed using 
aggregated rat antibody which binds by its Fc portion to receptors 
on FDC. As for the FDC-M1 mAb, the rat antibodies were visual- 
ized using the mouse anti-rat IgG reagent conjugated to peroxidase. 
Cell  Fusions.  mCTLA4-Hyl  transgenic  mice  and  normal 
CS7BL/6 were primed with 100/zg NP coupled to NP-C3,G in 
alum. 6 wk later they were boosted with 100/xg NP-CyG i.p., 
and 3 wk after that received a tertiary immunization with 100/~g 
i.p.  NP-CyG. 4 d after tertiary immunization,  spleen cells from 
individual mice were fused with the myeloma fusion partner, Sp2/0 
(21), using polyethylene glycol 1500 (Boehringer Mannheim).  Fused 
cells were resuspended in IMDM supplemented with 2-ME (5  x 
10 -s M), 10% FCS, r-glutamine, penicillin, and streptomycin,  and 
plated into six 96-well flat-bottomed plates to which 5  x  104/well 
peritoneal feeder cells had previously been added. 24 h later, hypox- 
anthine, aminopterin, and thymidine (HAT) were added. Superna- 
tants from wells were screened for h-bearing anti-NP antibodies. 
Positive  wells  were  subcloned  in  hypoxanthine and  thymidine 
medium containing supernatant from an IL6-secreting hybridoma 
to improve cloning efficiency. 
Preparation of RNA, cDNA, PCR Amplification, and Subcloning 
intopBluescript Vectors.  RNA from cloned hybridomas that secreted 
anti-NP antibodies were prepared as described  elsewhere  (22). 
First-strand cDNA was synthesized using a kit (Boehringer Mann- 
heim), and this served as template for subsequent PCR reactions. 
The primers used to amplify the variable regions of IgM and 
IgG hybridomas were as described in (23): IgM, 5'(GCTCTCGCA- 
GGAGAC)3'; IgG, 5'(GGCCAGTGGATAGAC)Y.  To amplify the 
V186.2 and related genes, a primer binding to the 5' region of the 
mature transcript was created: V, 5'(CCACTCCCAGGTCCA)3'. 
Purified PCR fragments were directly subcloned into pBluescript 
vector (Stratagene, Inc., LaJolla, CA). Briefly, the pBluescript vector 
was digested with EcoRV restriction enzyme (Boehringer Mann- 
heim), and the linearized vector tailed with ddTTP using terminal 
transferase (Boehringer Mannheim). The purified PCR products 
were ligated with the ddT-tailed  vector preparation with ligase 
(Boehringer Mannheim) overnight at 16~  and then transformed 
into competent Escherichia coli. 
The insertion of the PCR fragment was confirmed by prepara- 
tion of plasmid DNA, digestion with enzymes, and agarose gel 
electrophoresis. 
Sequencing Reactions.  Inserts from positive pBluescript  clones 
were sequenced on both strands using plasmid primers and sequenase 
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primers used to initiate DNA polymerase transcription in the se- 
quencing reactions were: 5' pBluescript 5'(GTAAAACGACGGCC- 
AGT)Y; and 3'pBluescript 5'(AACAGCTATGACCATG)3'. 
Stimulation of  B Cells In Vitro with Soluble CD40 Ligand (mCD40L- 
mCD8o  O.  Splenic  B cells were prepared from mice as previously 
described (16). 200,000 lymphocytes/well in a 96-well plate from 
control littermates or mCTLA4-H3'I  transgenic mice were cul- 
tured for 3 d in the presence  of  medium alone (10% FCS containing 
glutamine, penicillin, streptomycin, and 2-ME), LPS (50/xg/ml) 
(Sigma Chemical Co.), or mCD40L-mCD8c~ (16) in combination 
with 1% supernatants  from murine IL-2-, IL-4-, and IL-5-secreting 
clones (24). Stimulations were done in the absence and presence 
of mCTLA4-Hyl (25 /xg/mt) final concentration (8). 1 #Ci of 
[3H]thymidine/well was added for the last 16 h of culture. All 
assays were done in triplicate. Variation between triplicate wells 
was <10%. 
Results 
Generation of  Mice Transgenic  for mCTLA 4-H3,1 and mCD40- 
Hyl.  Transgenic mice that expressed soluble mCTLA4-Hyl 
and mCD40-Hyl were created as described in Materials and 
Methods. We identified three independent founder mice ex- 
pressing mCTLA4-Hyl. All lines had the same phenotype. 
The expression  of the transgenes is controlled by the mouse 
immunoglobulin heavy chain core enhancer and kappa pro- 
moter (25),  and the protein is expressed  and secreted prin- 
cipally in B cells and plasma cells, although there is detect- 
able transcription in RNA from thymus (26), suggesting some 
low level of transcription in T  cells. The mouse B cell im- 
mune system is not mature at birth but by 6 wk of age stable 
levels of expression  (between 10 and 30/xg/ml) of the trans- 
genic chimeric protein are achieved in the serum. 
The capacity of these soluble molecules to bind and inter- 
fere with the normal interaction between receptor and ligand 
is dependent on: (a) the molar concentration of the soluble 
transgenic  protein  and  the  affinity of interaction  of the 
ligand-receptor pair; and (b) accessibility of the soluble com- 
petitor to the ligand. 
The  molar  concentrations  of free  mCTLA4-H3,1  and 
mCD40-H3,1  are ~10-7 M in these transgenic mice.  The 
affinity/avidity of mCTLA4-Hyl  for  B7/BB1  is  in  the 
nanomolar range (27).  We have tested the binding at 37~ 
of sera from transgenic mice, and have observed that binding 
to activated B cells expressing B7/BB1 is saturated. In our 
hands, mCD40-Hyl binds less well to CD40 ligand (CD40L), 
at least compared with a decameric form of CD40, hCD40- 
H# (28), which probably accounts for the failure of mCD40- 
H'y1 to block CD40L.  In addition, mCD40L is only up- 
regulated after cognate interactions, so mCD40-Hyl may have 
less opportunity to compete with the physiological ligand. 
Both mCTLA4-H3'I and mCD40-Hyl transgenic mice 
are healthy; there is no obvious difference from normal mice 
in their survival and fertility. They are tolerant to the soluble 
transgene just as they are  to their own immunoglobulin. 
Grossly by FACS  |  analysis (Becton Dickinson & Co., Moun- 
tain View,  CA), the proportions of B, CD4 +, and CD8 + 
cells are normal in the spleen and lymph node, although spleen 
and lymph nodes are smaller in mCTLA4-Hyl transgenic 
animals (data not shown). The size difference  seems to be 
attributable to the lack of germinal centers in these animals 
(see later). 
Impaired  T-dependent but  Not  T-independent  Responses. 
Groups of mCTLA4-Hq,1 (Fig. 1 A) or mCD40-H3/1 (Fig. 
1 B) transgenic mice and their nontransgenic littermates were 
immunized with the T-dependent antigen DNP-KLH, ini- 
tially in alum, and boosted with soluble antigen at the times 
indicated by arrows.  There was no significant difference be- 
tween mice transgenic for mCD40-H3'I and control animals, 
indicating that the introduction of the transgenic construct 
did not nonspecifically impair immunoglobulin production. 
In contrast, mCTLA4-Hq/1 transgenic mice made a negligible 
primary antibody response, and secondary responses were at 
least an order of magnitude lower than in control animals. 
This was not because antibody responses  are simply slower 
in mCTLA4-H3,1 transgenic mice, as normal antibody levels 
were not achieved at longer intervals after immunization nor 
even after tertiary immunization. 
In contrast to T-dependent responses, mCTLA4-H3,1 trans- 
genic mice make normal responses to the T-independent an- 
tigen, TNP-Ficoll (Fig.  2 A). Cross-linking surface immu- 
noglobulin, as T-independent antigens might be expected 
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Figure  1.  Total  anti-DNP antibody  responses after  immunization  with 
DNP-KLH  in: (A) mice  transgenic  for mCTLA4-H3'I  (0) and their  con- 
trol nontransgenic  littermates  (O); and (B) mice transgenic  for mCD40- 
Hyl (0) and their  control nontransgenic  littermates  (O). Mice were im- 
munized where indicated  by arrows with 100/xg/ml  of DNP-KLH. The 
protein was alum precipitated for initial  immunizations;  all boosts were 
with soluble  antigen. Results  show mean and standard  deviation  for four 
mice in each group. Controls  were nontransgenic  littermates.  The results 
are representative of at least three experiments. 
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H3'1 and their control littermates  after immunization with: (A) control 
(O) and transgenic (O) anti-TNP  antibody titers after immunization  with 
TNP-Ficoll. Timecourse and levels of IgM and IgG3 anti-TNP antibody 
at day 7. (B) DNP-KLH as in Fig. 1 a. Distribution of anti-DNP isotypes 
at day 14, 7 d after secondary challenge, and at day 42, 14 d after tertiary 
challenge with DNP-KLH. 
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Figure 3.  Total levels of antibody lsotypes:  (A) mice transgenic for 
mCTLA4-H3'I (O) and their control nontransgenic  littermates (O); (B) 
mice transgenic for mCD40-H3,1 (O) and their control nontransgenic lit- 
termates (O). Samples were from 12-wk-old mice and were measured by 
radial immunodiffusion. 
to do, upregulates B7/BB1 on B cells (4). These data would 
suggest  that binding of mCTLA4-H'y1 to B7/BB1  exerts 
its effect by blocking an interaction with T cells rather than 
by acting directly on B cells. 
Total Isotypes and Antihapten Isotypes.  mCD40-Hyl trans- 
genic animals had normal isotype-specific antihapten anti- 
body responses to both T-dependent and T-independent an- 
tigens  (data not shown). Measurement of isotype specific 
antihapten  antibodies  in  mCTLA4-Hyl  transgenic  mice 
showed that levels of anti-DNP IgM antibodies overlapped 
in control and transgenic groups, but the IgG isotypes, IgG1, 
IgG2b, and IgG3, were ,'ol0-fold lower in transgenic animals 
(Fig. 2 B). In contrast,  levels of IgM and IgG3  anti-TNP 
antibodies, the principal isotypes elicited by TNP-Ficoll, were 
comparable  (Fig. 2 A). 
The decrease in IgG-specific anti-DNP titers was reflected 
in the total levels of IgG isotypes in mCTLA4-Hyl trans- 
genic animals, which were again about an order of magni- 
tude lower than controls (Fig. 3 A). Levels of total IgG iso- 
types were comparable to controls in mCD40-H3d transgenic 
animals (Fig. 3 B). 
Impaired T-dependent Antibody Responses Are Not Due to a 
Direct Effect of mCTLA4-H3/1 on B Cells.  One possible ex- 
planation  for the impaired T-dependent responses in these 
animals was that mCTLA4-H3'I co-cross-linked B7 on acti- 
vated B cells with Fc receptors and specifically downregu- 
lated T-dependent antibody responses. To test this we took 
B cells from transgenic and control mice and stimulated them 
with either LPS (T-independent stimulus) or a soluble form 
of CD40L that we have previously generated (16) in the pres- 
ence or absence of mCTLA4-H3'I (Table 1). CD40L induces 
the expression of B7-1ike molecules on B cells as has been 
reported by others (6, 29). Neither transgenic or control B 
cells were inhibited by the presence of mCTLA4-H3,1,  sug- 
gesting that mCTLA4-H3,1 exerts its effect  in vivo by blocking 
a specific  interaction with T cells, and not by co-cross-linking 
B7 with Fc receptors. 
Lack  of Germinal  Centers and  Trapping of Antigen  on 
FDCs.  Tissue sections from mCTLA4-H3'I and mCD40- 
H3,1 transgenic mice were incubated with antibodies directed 
against human 3'1. Lymph node sections from these mice are 
shown in Fig. 4, A andB. In tissue from the mCTLA4-H3'I 
mice (Fig. 4 A), plasma cells in the medullary areas are la- 
beled (thick arrows) as expected, since they secrete the trans- 
gene. Also labeled are dendritic cells in the T cell areas (smallest 
822  B Cell Function in Mice Transgenic for mCTLA4-Hyl Table  1.  Proliferation  of L]/mphocytes as Assessed by Uptake of ~H]Thymidine 
Animal  mCTLA4-H3'I  Medium alone  LPS  CD8c~-mCD40L 
5O ~g/ml 
Control  1  -  7,385  146,765  40,489 
+  4,651  145,395  37,121 
Control 2  -  4,081  138,506  37,806 
+  3,791  127,880  32,643 
Transgenic  1  -  2,147  84,376  26,113 
+  1,712  85,556  29,078 
Transgenic  2  -  1,832  86,858  28,757 
+  2,452  110,304  48,443 
200,000 lymphocytes/well  in a 96-well plate from control littermates or mCTLA4-H'y1 transgenic mice were cultured for 3 d in the presence of 
medium alone, LPS (50 #g/ml), or mCD40L-mCD8ot in combination with 1% supernatants from IL-4-, IL-5-, and IL-6-secreting clone~. Stimula- 
tions were done in the absence and presence of mCTLA4-H3,1 (25/~g/ml, final concentration). 1 /~Ci of [3H]thymidine/well was added for the 
last 16 h of culture. All assays were done in triplicate. Variation between triplicate wells was <10%. 
arrows) and FDC in the primary follicles (long arrows). Tissue 
from mCD40-H3"I transgenic mice (Fig. 4 B) also showed 
plasma cell labeling (not seen in this micrograph) but none 
associated with  accessory cells in  the germinal  center  (gc) 
or paracortex.  The monoclonal antibody FDC-M1 revealed 
that the FDC network was less extensive in mCTLA4-H3'I 
transgenic animals (Fig.  4 C) in comparison with nontrans- 
genic mice (Fig.  4 D). 
The most striking abnormality in the mCTLA4-H3'I trans- 
genic mice is the lack of germinal  centers in  their  spleens 
and lymph nodes. The absence of germinal centers was shown 
histologically using sections of tissue labeled in vivo with 
bromodeoxyuridine (data not shown), or stained in vitro with 
PNA (f =  primary follicle;  Figs.  4, A  and C and 5, A  and 
C). Even after four immunizations  with either DNP-KLH 
or NP-C3'G, only occasional very small loci of proliferation 
could be identified in mCTLA4-H3'I transgenic mice. This 
was in  marked  contrast  to  the mCD40-H3'I  and  control 
animals  in  which  germinal  centers  (gc;  Figs.  4  B  and  5, 
B and D) developed normally.  Fig. 5 A  shows the presence 
of anti-NP  producing  plasma  cells  in  NP-C3"G  immune 
mCTLA4-Hq/1 mice and the absence of NP-immune com- 
plex localization  on FDC in the adjacent primary follicle. 
Tissue  from  control  mice  (Fig.  5  B)  localized  the  NP- 
containing  immune  complexes on FDC,  formed germinal 
centers, and developed NP-specific plasma cells.  In contrast 
to the spleen and lymph node, gut-associated lymphoid tissue 
from the mCTLA4-H3"I  transgenic  mice had normal ger- 
minal  centers and levels  of serum IgA were elevated. 
A  second marked anomaly in the mCTLA4-H3"I  trans- 
genics is their failure to localize immune complexes (Fig.  5 
C).  This may be due to the low levels  of IgG isotypes in 
their serum,  as IgG complexes have been shown to localize 
much better than those of IgM (30). However, passive im- 
munization of mCTLA4-H3'I transgenic mice with high titer 
anti-DNP  IgG  antibody  followed by immunization  with 
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DNP-KLH did not restore germinal center formation, whereas 
control mice responded normally (data not shown), gc for- 
mation (Figs.  4 B and 5 D) and immune complex localiza- 
tion (Fig. 5 D) were normal in mCD40-H3'I transgenic mice. 
Lack of  Selection and Reduced Somatic Mutation in mCTLA 4- 
H3"I Transgenic Mice.  In view of the absence of germinal 
centers,  we tested for somatic mutation  in the mCTLA4- 
H3'1 transgenic mice. In C57BL/6 mice the primary T-depen- 
dent response to NP is dominated by antibodies expressing 
a particular  V.  gene,  186.2,  in  association  with  hl  light 
chains,  and this subset of antibodies is also evident in sec- 
ondary and tertiary immune responses to NP (31). 
We therefore hyperimmunized mCTLA4-H3,1 transgenic 
and control mice with NP-C3'G to maximize the chance of 
inducing somatic mutation.  4 d after the tertiary boosting, 
fusions were made in the standard manner.  Positive hybrid- 
omas were identified by binding to NP and by their expres- 
sion of X light chains.  There were several pronounced differ- 
ences between control and mCTLA4-H3,1 transgenic mice. 
First, the frequency of hybridomas was much higher in normal 
mice. We characterized  11 h-bearing anti-NP hybridomas from 
a normal mouse. 10 of these mAbs were 3'1 isotype and one 
expressed 3'2a.  From 2 mCTLA4-H3"I transgenic mice, we 
found 10 hybridomas. Six hybridomas expressed IgM heavy 
chain isotype, three IgG3, and only one IgG1. We sequenced 
six of these clones and compared them with three sequences 
from the normal mice. The sequences of the V. regions of 
these hybridomas,  are shown in Fig.  6. 
The three hybridomas shown from normal mice (C039, 
C041, and C043) all express V.186.2 heavy chains,  together 
with  the DFL16.1 D  segment and JH2.  All three hybrid- 
omas have extensive somatic mutations  in their V  regions 
(Fig.  6 A).  In particular  all have a mutation at amino acid 
position 33, encoding a change from tryptophan to teucine. 
This mutation  has  been shown to increase the affinity for 
NP 10-fold (31). They have different NH2-terminal diversity Figure  4.  Light micrographs of lymph nodes from transgenic and control mice (x80). (A) Immunoperoxidase labeling with antibodies against human 
3'1 in mCTLA4-H3"I transgenic mice showing staining of plasma cells (thick arrows), which produce the transgenic protein, the FDC network (long 
arrows), and dendritic cells in the paracortex (small arrows). (B) Immunoperoxidase labeling with antibodies against human 3'1 in the control mCD40-H3`I 
transgenic mice show no such localization of the transgenic product on FDC or dendritic cells, although plasma cells producing the mCD40-H3`I 
are present in the medullary region but are not seen in this micrograph. (C) Labeling of the FDC network with FDC-M1 in mCTLA4-H3,1 mice. 
(D) Labeling of the FDC network with FDC-M1 in nontransgenic controls. Figure 5.  Light micrographs showing NP-specific antibody and aggregated antibody localization in tissue from transgenic or control mice (x80). 
(A) Immunoperoxidase  localization of anti-NP producing plasma cells (dark brown) in the spleen of immune mCTLA4-H'yl mice are seen as three 
clusters adjacent to a nonlabeled follicle (f). (B) The spleen from a nontransgenic  immune mouse prepared at the same time point post immunization 
as seen in A, contains not only the NP-specific antibody producing cells (dark brown) but also localizes the NP-containing  immune complexes on FDC 
(light brown) and forms gc's. (C) Micrograph  shows lack of ability of FDC from mCTLA4-H',/1  mice to trap antibody aggregates. (D) Localization 
of antibody aggregates by FDC in control mCD40-H'y1 transgenic mice. A 
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V186.2 sequences obtained from transgenic (T) and control (C) mice 
1  CDRI 
CAG  GTC  CAA  CTG  CAG CAG  CCT  GGG GCT  GAG CTT GTG AAG CCT GGG GCT TCA GTG AAG CTG TCC TGC AAG GCT  TCT GGC TAC ACC  TTC ACC  AGC  TAC TC~ 
................................................................................................... 
.................................................................................................  T- 
....................  C  ............................................................  --G  ........  A  .....  T- 
..........................................................................................  -C  .....  TA 
i00  CDR2 
Aq~G CAC  TGG  GTG  AAG  CAG  AGG  CCT  GGA  CGA GGC CTE GAG TGG A~'F GGA AC~ AT'P GAT CCT AAT AG~  GG~ C~GT AC'P AAC. T~  AA~ GAG  AAG ~  AAG AC.C 
................................................................................................... 
................................................................................................  -C- 
...............................................................  C  ......  A  ......  A  ..................... 
...........................................................  A  .....................  G  ...............  A- 
199 
AAG  GCC  ACA  CTG  ACT  GTA  GAC  AAA  CCC TCC AGC ACA GCC  TAC ATG CAG CTC AGC AGC CTG ACA  TCT GAG  GAC TCT GCG GTC  TAT TAT  TGT GCA AGA 
................................................................................................ 
............................................  A  - -A  ....  A ........................................... 
.......................  T  ............................  A ........................................... 
........................  T .......  G  ......  '  .....................  T ................................... 
non classical anti-NP genes from transgenic mice 
1 
CAG  GTC  CAA  CTG  CAG  CAG  CCT  GGG ACT  GAA CTG GTG AAG  CCT GGG GCT TCA GTG AAG CTG TCC TGC AAG GCT TCT GOC  TAC ACC  ~  ACC  AGC TAC TGG 
.................................................................................................... 
100 
ATG  CAC  TGG  GTG AAG  CAG AGG  CCT  GGA CAA GGC CTE GAG TGG ATE GGA AAT ATE AAT CCT AGC AAT GGT GGT ACT AAC  TAC AAT  GAG AAG  TTC AAG AGC 
................................................................................................... 
199 
AAG  GCC ACA  CTG  ACT  GTA GAC  AAA  TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC  TAT TAT  TGT GCA AGA 
................................................................................................ 
i 
CAG  GTC  CAA  CTG  CAG CAG  CCT  GGG GCT GAG  CTE GTG AAG CCT C~3G GCT TCA GTG AAG  CTG TCC TGC AAG  GCT TCT GGC TAC ACC  TTC ACC AGC  TAC  TGG 
................................  G  ........................  A  ......................................... 
I00 
ATG  CAC  TGG  GTG AAG  CAG AGG  CCT GGA  CAA GGC CTT GAG  TGG ATC GGA GAG ATT GAT CCT TCT GAT AGT TAT ACT AAC  TAC AAT  CAA AAG  TTC AAG GGC 
...........................................................................  -G  ...................... 
199 
AAG  GCC  ACA  TTG  ACT  GTA  GAC AAA  TCC TCC AGC  ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA  TCT GAG GAC TCT GCG GTC  TAT TAC  TGT GCA AGA 
................................................................................................ 
1 
CAG  GTC  CAG  CTG  CAG  CAG  TCT  GGA  GCT GGG CTG GTG AAA CCC GGG GCA TCA GTG AAG CTG TCC TGC AAG GCT TCT GGC  TAC ACC  TTC ACT  GAG TAT ATT 
................................................................................................  -C- 
100 
ATA  CAC  TGG  GTA  AAG  CAG  AGG  TCT GGA  CAG GGT CTT GAG TGG ATE GGG TGG TTT TCA CCT GGA AGT GGT AGT ATA AAG  TAC AAT  GAG AAA  TTC AAG GAC 
................................................................................................... 
199 
AAG  GCC  ACA  TTG  ACT  GCG  GAC AAA  TCC TCC AGC ACA GTC TAT ATG GAG CTT AGT AGA ~f(3 ACA  TCT GAA GAC  TCT GCG GTC TAT  TTC TGT  GCA AGA 
................................................................................................ 
1 
CAG  GTC  CAA  CTG  CAG  CAA  CCT  GGG  TCT GAG CTG  GTG AGG CCT GGA GCT TCA GTG AAG CTG TCC TGC AAG  GCT TCT GGC TAC ACA  TTC ACC  AGC  TAC TGG 
................................................................................................ 
100 
ATG  CAC  TGG  GTG  AAG  CAG  AGG  CCT  GGA  CAA GGC CTT GAG TGG ATE GGA AAT ATE  TAT CCT GGT AGT  GGT AGT ACT AAC  TAC CAT  GAG AAG  TTC AAG AGC 
................................................................................................... 
199 
AAG  GCC ACA  CTG  ACT  GTA  GAC ACA  TCC  TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG  GTC TAT  TAC TGT ACA 
.............................................................................................. 
1 
CAG  GTC  CAA  CTG  CAG  CAG  TCT  GGG GCT  GAA CTG GTG AAG CCT GGG GCT TCA GTG AAG TTG TCC TGC AAG  GCT TCT GGC TAC ACC  TTC ACC AGC  TAC TAT 
................................................................................................... 
100 
AT(;  TAC  TGG  G~G  AAG  CAG AGG  CCT GGA  CAA GGC CTT GAG TGG ATE GGA GAG Aq'~ AAT CCT AGC AAT GGT GGT ACT AAC  TTC AAT  GAG  AAG  TTC AAG AGC 
................................................................................................... 
199 
AAG  GCC ACA  CTG ACT  GTA  GAC AAA  TCC  TCC AGC ACA  GCA TAC ATG CAA CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG  GTC TAT  TAC TGT ACA  AGA 
................................................................................................ 
S  DJ sequences obtained from transgenic (T) and control (C) mice 
N  D 
Germline  DFL16.1  JH4  TTTATTACTACGGTAGTAGCTAC 
TDJ077  DFLI  6 .  1  JH4  G  CTACGGTAGTAGC 
TDJ142  DFL16.1  JH4  TGTT  TTACTACGGTAGTAGCTA 
TDJ215  DFL16.1  JH4  TCCTCC  TATTACTACGGTAGTAGC 
Germl  ine  DFL16.1  JH2  TTTATTACTACGGTAGTAGCTAC 
TDJ099  DFL16 .  1  JH2  TATG  ATTACTACGGTAGTAGC 
TDJ210  DFL16.1  JH2  AGATT  TTACTACGGTAGTAGCTAC 
CDJ039  DFLI6.1  JH2  TATTACTACGG 
CDJ041  DFL16.1  JH2  TATTACTACGGT 
CDJ049  DFLI6.1  JH2  TACG  ATEACTACGGTAGTAG 
Germline  DSP2.2  JH3  TCTACTATGATTACGAC 
TDJ093  DSP2.2  JH3  GGG  TACGAC 
GAC 
CCGC 
TAC 
T 
GGG 
N  J 
TAC TAT GCT ATE GAC TAC TGG GGT CAA GGA ACC  TCA GTC ACC  GTC  TCC  TCA 
C  ................................................ 
AC  .......  -G  ....................................... 
TAC  ................................................ 
TAC ~  GAC TAC TGG GGC CAA GGC ACC ACT  CTC ACA  GTC TCC TCA 
............................................. 
............................................. 
............................................. 
.........  -C  .................................. 
............................................. 
GCC TGG TTT GCT TAC TGG GGC CAA GGG ACT CTG  GTC ACT  GTC  TCT GCA 
................................................ 
Figure  6.  (A) Nucleotide sequences of the V. genes expressed in the hybridomas of C (control) 39, C41, C43, and T(transgenic)  77,  T93, T99, 
T142, T210, and T215.  Mice were primed and boosted  twice, the last immunization 4 d before fusion (see Materials and Methods).  Also shown are 
the sequences of the germline V, genes (V186.2, J00534,  X00160,  X02066, M15228,  and M64142).  V186.2 encodes the classical anti-NP heavy chain 
variable region associated with lambda in C57BL/6.  The other genes are coded by their accession numbers for the EMBL database. Underlined are 
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related. 
Only one hybridoma,  clone T099,  from the mCTLA4- 
H3'1 mice expressed V.186.2 in association with DFL16.1 
and JH2.  The V. of this hybridoma was unmutated.  The 
3' junction of the DJ border shows no N sequence diversity, 
a characteristic  feature of primary response hybridomas  to 
NP (31).  The five other hybridomas expressed different V. 
genes.  Clone T077 expressed V.23, a V. gene identified in 
the T-independent response to NP-Ficoll (32).  Clone T093 
expressed V.124 (33), a V. gene closely related to V.186.2 
but expressed by the BALB/c Ig  ~ immunoglobulin haplotype 
in the response to NP. The mCTLA4-H3"I mice were gener- 
ated in  (DBA/2  x  C57BL/6)F1  mice and  although  they 
have been backcrossed onto C57BL/6 and are homozygous 
at the MHC,  they may still  carry genes from the DBA/2 
background.  DBA/2 express the IgH a haplotype, of which 
V,124  is  a member.  Clone  T142  expresses V~102.1,  a VH 
gene closely related to V.186.2 (34).  Clone T210 expresses 
a V. gene expressed in the anti-DNP response in association 
with )x light chains (35). Clone T210, like T077, and T093 
express a proline (CCT) at position 7, a distinguishing  fea- 
ture  of C57BL/6  NPb-related genes (36). 
All clones but one, from either transgenic or control mice, 
use DFL16.1 in association with either JH4 (three cases) or 
JH2 (five cases).  The exception is hybridoma T093,  which 
uses V.124,  the IgH a V.186.2  equivalent  gene,  in associa- 
tion  with  DSP 2.2 and JH3. 
While all control hybridomas are extensively somatically 
mutated, there are only four mutations in the transgenic hy- 
bridomas, clones T093 and T142. Because the V.186.2 gene 
family is so large, it is difficult to be sure that these are not 
closely related  germline  genes  (32).  However, we also  se- 
quenced the ~, light chains (data not shown). The three normal 
hybridomas had five mutations in the Vr, whereas only one 
mutation was detected in the six transgenic hybridomas. Hy- 
bridoma T099  had no light  chain  mutations. 
We made a comparative estimate of the affinities  of the 
hybridomas by the method of Herzenberg et al.  (20).  The 
binding  of T099  represents  the  affinity  of the  germline 
V.186.2.  As has been observed previously, the high affinity 
hybridomas, C039, C041, and C043, from the normal mouse 
bound  at  least  as  well  to  the  low  haptenated  protein 
NPnBSA in ELISA compared to NP3sBSA, whereas T099 
bound less well to NPllBSA than NP38BSA. The pattern for 
the other transgenic derived hybridomas was qualitatively the 
same as T099,  suggesting they had lower affinities  for NP 
than  the control derived hybridomas  (data not  shown). 
Discussion 
This  paper  investigates  in  detail  the  defective antibody 
production  in  mCTLA4-H3d  transgenic  mice.  In  many 
respects these transgenic  mice look phenotypicaUy like athymic 
nude  mice.  They have levels  of IgM  antibody within  the 
normal range, but IgG isotypes are reduced, and they make 
normal TI-2 antibody responses. Unlike athymic mice, how- 
ever, they make a T-dependent response to protein antigens, 
but with a greatly reduced IgG titer. To rule out the possi- 
bility that  the defects in antibody production might be at- 
tributable to the expression of the transgene in B cells and 
plasma cells, we expressed mCD40-H~r  as a transgene. The 
mCD40-H3d transgenic mice make antibody responses in- 
distinguishable from those in normal mice. Another possi- 
bility is that the transgenic protein binds to CTLA4-1igand 
expressing cells which are then removed either by an interac- 
tion with complement or by antibody-dependent ceU-mediated 
cytotoxicity. We think this unlikely as the dendritic cell ar- 
chitecture in  T  cell areas,  where B7 and related molecules 
are constitutively expressed, looks quite normal. In addition 
it seems unlikely that mCTLA4-H71 specifically downregu- 
lates B cell responses by co-cross-linking CTLA4-1igands and 
Fc receptors on B cells, as mCTLA4-H'y1 did not reduce the 
proliferation  of B cells  stimulated with  soluble CD40L,  a 
T-dependent  stimulus  that  induces  the expression of B7. 
The functional defect in antibody production in mCTLA4- 
H3d transgenic mice is correlated with profoundly impaired 
gc formation, the cardinal feature of T-dependent antibody 
responses,  gc's are locations where a few B cell precursors 
(37) proliferate at enormous rates  (38) after immunization 
with T-dependent  antigens.  At least one of the important 
functions of gc's,  therefore, is clonal amplification.  Second, 
it is clear that germinal centers are sites where immunoglob- 
ulin class switching  can occur.  Follicular B cell blasts,  the 
immediate precursors of the gc reaction, express IgM. Cen- 
trocytes, the progeny of germinal center centroblasts, almost 
invariably express IgG and IgA isotypes (39).  In addition, 
it  has  been proposed that  somatic mutation  is  specifically 
switched on in B cells  here (40),  and the accumulation  of 
somatic mutations  in  germinal  centers  has been elegantly 
confirmed using microdissection and PCR (41).  Finally,  it 
is considered likely that long-term antibody responses are main- 
tained by the continuous stimulation of B cells with antigen 
retained on FDCs (42).  With respect to these aspects of gc 
function, mCTLA4-Hyl transgenic mice, with no gc's, be- 
have as one might predict. They make poor responses to pro- 
tein antigens, and have limited class switching. Furthermore, 
analysis  of VH gene usage in the anti-NP response indicates 
the CDR1 and CDR2 regions of the V186.2 gene. Dashes indicate sequence homology with the corresponding germline sequence. Mutations are 
indicated by the appropriate letter. Silent mutations are in roman; nonsilent mutations are in boldface. (/3) DJ sequences  obtained from the hybridomas. 
Shown are the hybridoma, T (transgenic), and C (control), the corresponding D and J segments, and the nucleotide sequence  showing 5' N region 
diversity, the D fragment, 3' N region diversity, and finally the J segment. 
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of B cells with high affinity for antigen.  As in the T-inde- 
pendent response to NP (32), many V. genes closely related 
to V.186.2  but of low affinity are represented. 
B cells are activated initially in the T cell areas in T-depen- 
dent responses (39, 43, 44) where CTLA ligand is expressed 
on interdigitating  cells (5, 8).  It is possible that  some pri- 
mary signal is blocked at this location in mCTLA4-H3,1 trans- 
genic mice. However, staining of sections from mCTLA4- 
H3,1 transgenic mice showed localization of CTLA4 ligand 
on  the  FDC  network,  where  it  may  have  been  trapped 
nonspecifically from degraded B cells as has been shown for 
class II molecules (45). Alternatively, FDCs bearing CTLA4 
ligand may form a local environment where trapped antigen, 
B cells,  and the many T  cells located in this part of the gc 
interact. 
The earliest phase of the follicular reaction involves prolifer- 
ation of slg-positive cells that have not switched (39). This 
stage appears  to be profoundly blocked in mCTLA4-H3,1 
transgenic mice. The failure of these mice to class switch is 
reflected in the transgenic hybridomas. Virtually all hybrid- 
omas from normal mice express 3,1, whereas in transgenic 
animals #  and 3'3 were the predominant  isotypes, a profile 
more usually associated with T-independent responses (46). 
It is emphasized that gut-associated lymphoid tissue is not 
affected in the transgenic mice. There is no obvious reason 
for this as the transgenic protein is expressed in gut-associated 
plasma cells. 
Compared with normal mice, mCTLA4-H3,1 transgenic 
mice show reduced levels of somatic mutation.  This is con- 
sistent with  gc's being the principal  site of somatic muta- 
tion, although a few mutations were observed in the trans- 
genic hybridomas.  What is clear from these studies is that 
the affinity of the hybridomas generated in mCTLA4-H3,1 
transgenic mice is low. This is partly attributable to a lack 
of ability to selectively amplify B cells encoding high affinity 
germline  genes.  Somatic mutation  is  seen in V.  genes  in 
lower animals  like Xenopus,  which  nevertheless  have poor 
affinity maturation (47). It has been speculated that the failure 
of Xenopus  to make high affinity antibodies is caused by an 
inability to select mutants rather  than a failure to generate 
them by somatic mutation,  mCTLA4-H3,1 transgenic mice 
fail to localize immune  complexes on FDCs and hence, in 
addition to their other defects, fail to provide an appropriate 
microenvironment in which selection of high affinity B cells 
can take place. 
There  are  striking  similarities  between  these  mice  and 
human patients with an antibody deficiency associated with 
hyper IgM that  have a defect in the expression of CD40L 
on  T  cells  (48-50).  Both  have  low  IgG  levels,  impaired 
T-dependent  antibody responses, and an absence of gc for- 
mation.  Triggering of human T  cells through  CD3 is very 
poor at inducing the expression of CD40L (28).  However, 
it has recently been reported that B7/BB1 in conjunction with 
an anti-CD3  signal strongly upregulates CD40L (51). The 
defects in mCTLA4-H3,1 transgenic mice could be explained 
by a failure of CTLA4 ligand expressing cells to upregulate 
CD40L on activated T cells, which consequently fail to supply 
help for B cells. 
In  summary,  this  report  confirms  and extends previous 
studies (10) showing that mCTLA4-H3'I can inhibit T-depen- 
dent antibody responses.  It is not yet clear whether estab- 
lished antibody responses are similarly dependent on CTLA4 
ligand.  Enthusiasm  for mCTLA4-H3,1  as  a tool for sup- 
pressing T-dependent antibody responses must be tempered 
by the fact CD4 + T  cells are primed  normally.  It is now 
clear that there are many ligands for CTLA4/CD28  (6,  7, 
52). Differential sensitivity of these costimulatory molecules 
to the blocking effects of mCTLA4-H3,1 would readily ex- 
plain the apparent paradox that CD4 + cells are primed nor- 
mally in the  transgenic  mice described here. 
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